Publications

Trials

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial.

04-11-2021

Clinica chimica acta; international journal of clinical chemistry

Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications.

01-10-2021

Molecular cancer research : MCR

The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics.

01-10-2021

Nature cell biology

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.

01-09-2021

Prostate cancer and prostatic diseases

The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.

01-09-2021

Cancers

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation.

27-08-2021

Cancer reports (Hoboken, N.J.)

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.

01-08-2021

European urology oncology

Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.

01-08-2021

Molecular oncology

Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.

01-07-2021

Scientific reports

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.

01-07-2021

European urology focus

Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.

01-07-2021

Cancer chemotherapy and pharmacology

Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours.

01-06-2021

Genome biology

Functional mapping of androgen receptor enhancer activity.

11-05-2021

Future oncology (London, England)

The intravenous to oral switch of taxanes: strategies and current clinical developments.

01-04-2021

Nature communications

The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair.

15-01-2021

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.

01-01-2021

European urology

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.

01-12-2020

JAMA network open

Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.

01-10-2020

BMC cancer

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.

14-09-2020

Nature communications

Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.

09-09-2020

Key Publication

International journal of cancer

A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.

15-08-2020

Nature genetics

Prostate cancer reactivates developmental epigenomic programs during metastatic progression.

01-08-2020

Nucleosides, nucleotides & nucleic acids

Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase.

31-07-2020

Future oncology (London, England)

Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer.

01-07-2020

bioRxiv

Human Prostate Cancer-Associated Macrophage Subtypes and Prognostic Potential Revealed by Single-cell Transcriptomics

20-06-2020

Key Publication

Prostate cancer and prostatic diseases

Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer.

01-06-2020

European journal of cancer (Oxford, England : 1990)

Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme.

01-05-2020

Clinical genitourinary cancer

Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.

01-02-2020

Endocrine-related cancer

Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program.

01-02-2020

eLife

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

19-12-2019

Cancer cell

Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors.

09-12-2019

Pharmacotherapy

Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer.

01-12-2019

Nature communications

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

20-11-2019

Pharmaceutical research

Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study.

15-11-2019

Clinical genitourinary cancer

Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.

01-10-2019

Clinical genitourinary cancer

Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant.

01-10-2019

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Assessment of Simplified Methods for Quantification of ¹⁸F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer.

01-09-2019

Endocrine-related cancer

Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers.

01-05-2019

Cancer cell

CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.

15-04-2019

Drugs & aging

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.

01-04-2019

Cancer medicine

Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.

01-04-2019

Clinical genitourinary cancer

Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis.

01-04-2019

The Journal of urology

Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer.

01-03-2019

Prostate cancer and prostatic diseases

Impact of age on exposure to oral antiandrogen therapies in clinical practice.

01-03-2019

Head & neck

HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.

01-02-2019

Life science alliance

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors.

01-02-2019

JCI insight

Frequent clonal relations between metastases and non-index prostate cancer lesions.

24-01-2019

Nature communications

Integrative epigenetic taxonomy of primary prostate cancer.

21-11-2018

Endocrine-related cancer

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond.

31-10-2018

Molecular oncology

Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.

01-08-2018

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial.

Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications.

The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics.

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.

The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation.

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.

Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.

Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.

Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.

Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours.

Functional mapping of androgen receptor enhancer activity.

The intravenous to oral switch of taxanes: strategies and current clinical developments.

The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair.

Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.

Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.

Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.

A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.

Prostate cancer reactivates developmental epigenomic programs during metastatic progression.

Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase.

Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer.

Human Prostate Cancer-Associated Macrophage Subtypes and Prognostic Potential Revealed by Single-cell Transcriptomics

Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer.

Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme.

Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.

Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program.

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors.

Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer.

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study.

Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.

Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant.

Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer.

Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers.

CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.

Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.

Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis.

Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer.

Impact of age on exposure to oral antiandrogen therapies in clinical practice.

HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors.

Frequent clonal relations between metastases and non-index prostate cancer lesions.

Integrative epigenetic taxonomy of primary prostate cancer.

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond.

Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.

This site uses cookies

Assessment of Simplified Methods for Quantification of ¹⁸F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer.